Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lyfe Capital
BioCentury | Mar 12, 2025
Deals
Building biotech ecosystems in Asia: an East-West Summit podcast
Takeaways from BioCentury’s East-West Biopharma Summit focus on Japan, India, China, plus the NewCo Model
BioCentury | Feb 6, 2025
Management Tracks
Arcturus appoints Slaoui chair designate
Plus: Affinia hires Makimura and Xu joins Sciwind
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Apr 3, 2024
Deals
With $1.8B ProfoundBio deal, Genmab gains chance to market ‘100% owned’ product
Along with ADC platform, the Danish antibody specialist gains a FOLR1-targeting product entering pivotal testing for ovarian cancer
BioCentury | Jan 30, 2024
Product Development
Singapore’s next challenge: turning momentum into sustainable growth
The island nation has caught the interest of international investors and pharmas. Will this be the moment its biotech accelerates?
BioCentury | Aug 3, 2023
Finance
Aug. 3 Quick Takes: Kyverna extends B round to $145M
Plus: Aravive low on cash after ovarian cancer miss, Agios to develop Alnylam program, and updates from Seagen and Amber
BioCentury | Jul 15, 2023
Finance
Out of the abyss: 3Q23 market preview
Biotech investors see the worst fading into the rearview mirror,
BioCentury | Apr 25, 2023
Finance
Could Singapore become the next global biotech hub?
Local investors, global VCs aim to shape Singapore’s next biotechs
BioCentury | Dec 1, 2022
Regulation
Nov. 30 Quick Takes: Ferring’s Rebyota wins FDA approval
Plus: Novo, Lyfe lead iECURE’s new round and updates from bluebird-argenx, Nimbus, Oncorus and more
BioCentury | May 16, 2022
Deals
May 16 Quick Takes: Agios again narrows focus
Plus Shionogi-F2G, Chimerix, Travere, Valneva and more
Items per page:
1 - 10 of 38